Approval of Cologuard (multi-target stool DNA test that examines KRAS mutation, NDRG4 and BMP3 methylations, β-actin, plus a hemoglobin immunoassay) [18] and Epi proColon (blood-based test that examines SEPT9 methylation) [14, 19, 20] by the Food and Drug Administration has further confirmed DNA methylation as an applicable biomarker for CRC screening. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.